摘要脂肪性肝病迎来了一次重要的更名，即代谢相关脂肪性肝病（MASLD）取代了非酒精性脂肪性肝病。MASLD的定义不再需要排除其他并存的肝脏疾病，而是将肝脏脂肪变性与超重/肥胖、2型糖尿病或代谢紊乱相关联，并对乙醇饮用量做了明确的界定。新的定义还引入了代谢相关酒精性肝病和隐源性脂肪性肝病等概念。这些变化将为脂肪性肝病药物临床试验的设计和目标人群选择带来新的挑战和机遇。

abstractsFatty liver disease has undergone a major name change, with metabolic dysfunction-associated fatty liver disease (MASLD) replacing nonalcoholic fatty liver disease. The definition of MASLD no longer requires the exclusion of other co-existing liver diseases but instead associates hepatic steatosis with overweight/obesity, type 2 diabetes mellitus, or metabolic disorders and clearly defines the amount of alcohol consumption. The new definition also introduces the concepts of metabolic-related alcoholic liver disease and cryptogenic fatty liver disease. These changes will bring new challenges and opportunities for the design of clinical trials of fatty liver disease drugs and the selection of target populations.